Richard Roseff, M.D.

*Offices:* 105B Newtown Road

 Danbury, CT 06810

 (203) 743-9596

 (203) 743-7597 (fax)

**MEDICAL LICENSE:**

Connecticut License #027620

**PROFESSIONAL CERTIFICATION:**

American College of Rheumatology, Board Certification, 11/1988

 American Board of Internal Medicine, Board Certification, 09/1984

 International Society of Clinical Densitometry, Certified Clinical Densitometrist, 08/1999

**HOSPITAL AFFILIATIONS:**

 Associate Attending, Danbury Hospital, Danbury, CT 09/1987 to Present

**MEDICAL SOCIETY MEMBERSHIPS:**

 American College of Rheumatology, Founding Fellow

 Boston University School of Medicine Alumni Association

 Southwestern Connecticut Rheumatism Society

 Connecticut Rheumatology Association

**CURRENT APPOINTMENTS:**

 **Rheumatologist, Sagebrush Health, 105B Newtown Rd, Danbury,CT 03/23 to Present**

**Consulting Rheumatologist, State of CT, Southbury Training School, Southbury, CT**

 **6/1994 to Present**

 **ACR “Advocates for Arthritis”, Connecticut Delegation to Capitol Hill, Washington, DC, 9/10-present**

**PRIOR APPOINTMENTS:**

 **Richard Roseff MD, LLC, Danbury and Ridgefield, CT 8/98 to 3/23**

 Consulting Rheumatologist, Arthritis Center of CT, Waterbury, CT 11/95 to 7/99

 Attending, Arthritis Clinic, Danbury Hospital, Danbury CT 11/89 to 2/92

 Medical Director, New Horizons, Unionvale, NY 11/88 to 4/00

 Internist/Rheumatologist, Associated Internists of Danbury, Danbury, CT 9/86 to 11/96

 -Founder and Director Physical Therapy Unit

 Internist/Rheumatologist, Northern Metropolitan Medical PC, Danbury, CT, Carmel, NY,

 Patterson, NY 11/96 to 7/98

 Instructor, Introduction to Clinical Medicine, Harvard Medical School, Boston, MA

 5/85 to 6/86

 Medical Unit, Mass. Eye and Ear Infirmary, Boston, MA 11/85 to 9/86

 Instructor, Boston University School of Nursing, Graduate Department, Boston, MA

 2/83 to 5/84

 Clinical Staff, Hull Medical Center, Hull, MA 8/82 to 8/86

 Instructor, Boston University School of Medicine, Boston, MA 7/81 to 7/84

**INTERNSHIP, RESIDENCY AND POSTGRADUATE TRAINING:**

 Clinical and Research Fellow in Rheumatology, Mass General Hospital, Boston, MA

 7/84 to 9/86

 Chief Resident in Internal Medicine, Boston Veterans Administration Medical Center,

 Boston, MA 7/83 to 7/84

 Resident in Internal Medicine, Boston Veterans Administration Medical Center,

 Boston, MA 7/81 to 7/83

 Internship in Internal Medicine, Boston Veterans Administration Medical Center,

 Boston, MA 7/80 to 7/81

**EDUCATION:**

M.D., Boston University School of Medicine, 1980

 B.A., Magna Cum Laude, Amherst College, Amherst, MA, 1976

**AWARDS:**

 2018 Medical Honoree of the Year, Arthritis Foundation, Rocky Hill, CT, 2018

 Young Investigator Award, Arthritis Foundation, 1986

 National Research Service Award, National Institute of Arthritis, Diabetes and Kidney

 Diseases, 1986

**PUBLICATIONS:**

 Roseff R, Wohlgethan J, Sipe J, Canoso, J, *The Acute Phase Response in Gout,*

 Rheumatology, October 1987, 994-7.

 Rosseff R, Canoso, J, *Femoral Osteonecrosis Following Soft Tissue Corticosteroid*

 *Infiltration*, The American Journal of Medicine, December 1984, 1119-20.

 Roseff R, *Time-dependant Effects of Selective Catecholamine Depletion upon the Acoustic*

 *Startle Response in Rats,* (Senior Honors Thesis, Amherst College, Amherst, MA, 5/76)

**SELECTED LECTURES:**

* “Update in Osteoporosis” 5/98

NBC Studios, Medical Division, Rockefeller Center, New York, NY

* “Therapeutic Management of Pain” 4/98

Charter Oak Conference, Connecticut APA, Newport, RI

* “Alternatives to NSAID Therapy” 9/97

Danbury Physicians’ Clinical Conference, Ridgefield, CT

* “Office Management of Osteoporosis” 4/97

Charter Oak Conference, Connecticut APA, Southbury, CT

* “ Radiographic Absorptiometry in Osteoporosis” 9/96

Imaging Center Series, New Britain Hospital, New Britain, CT

* “Advances in Osteoporosis” 4/96

 Southbury Training School Conference, Southbury, CT

* “Introduction and Overview” 9/95

 Moderator of Lyme Disease Symposium, Danbury, CT

* “Approach to the Shoulder” 4/95

 Rheumatology Symposium, Danbury Hospital, Danbury, CT

* “ Monoarticular Arthritis” 10/93

 Residents’ Conference, Danbury Hospital, Danbury, CT

* “Osteoarthritis and Rheumatoid Arthritis” 2/93

 Yorktown Medical Society, Yorktown, NY

* “Non-steroidals: What’s New?” 7/92

 St. Francis Hospital Residents’ Round, Poughkeepsie, NY

* “Causalgia” 11/90

 Medical Grand Rounds, Nyack Hospital, Nyack, NY

* “Anti-Cardiolipin Antibody Syndrome” 4/89

 Medical Grand Rounds, Danbury Hospital, Danbury, CT

* “The Rheumatic Manifestations of Systemic Disease” 4/89

Residents’ Conference, Danbury Hospital, Danbury, CT

* “Reiters Syndrome and the Spondyloarthropathies” 1/88

 Residents’ Conference,. Danbury Hospital, Danbury, CT

* “ Protaglandins and Leukotrienes” 11/87

 Residents’ Conference, Danbury Hospital, Danbury, CT

* “Introduction to Immunology” 10/85

 Critical Care Nurses’ Seminar, Mass General Hospital, Boston, MA

* “Pyogenic Sacroiliitis” 10/84

 Arthritis Grand Rounds, Mass General Hospital, Boston, MA

* “Selective IgA Deficiency Syndrome” 9/84

 Arthritis Grand Rounds, Mass General Hospital, Boston, MA

* “Takayasu’s Arteritis” 8/84

 Arthritis Grand Rounds, Mass General Hospital, Boston, MA

* “The Lupus Anticoagulant”

Arthritis Grand Rounds, Mass General Hospital, Boston, MA

* “Sarcoid Arthritis” 7/84

 Arthritis Grand Rounds, Mass General Hospital, Boston, MA

* “Rheumatoid Arthritis and Osteoarthritis” 5/83

 Allied Health School, Northeastern University, Boston, MA

**RESEARCH at CLINICAL RESEARCH CENTER of CT:**

**Principal Investigator**

* A 52-week, phase 3, multicenter, randomized, double blind, efficacy and safety study, comparing GSK3196165 with placebo and with tofacitinib in combination with conventional synthetic DMARDs, in participants with moderately to severely active rheumatoid arthritis who have an inadequate response to conventional synthetic DMARDs or biologic DMARDs. 2019
* A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis. 2019
* Prospective Observational Trial to Validate The Ability of PrismRA to Predict Non-Responders to anti-TNF Therapies. 2019
* A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy. 2019
* A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients with Axial Spondyloarthritis, 2018
* A Randomized, double-blind, parallel-group, multicenter study of secukinumab to compare 300mg and 150 mg at Week 52 in patients with Ankylosing Spondylitis who are randomized to dose escalation after not achieving inactive disease during an initial 16 weeks of open-label treatment with secukinumab 150mg. (ASLeap) 2018
* A multicenter, randomized, double-blind, active and placebo-controlled 16 week study followed by long term evaluation of efficacy and safety of Ixekizumab (LY2439821) in bDMARD-naïve patients with radiographic axial spondyloarthritis, 2016
* A multicenter, randomized, double-blind, placebo-controlled 16 week study followed by long term evaluation of efficacy and safety of Ixekizumab (LY2439821) in TNFi-experienced patients with radiographic axial spondyloarthritis, 2016
* A 52 week multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Ixekizumab (LY2439821) in bDMARD-naïve patients with Nonradiographic axial spondyloarthritis, 2016
* A phase 3, multicenter study to evaluate the long-term safety and efficacy of Baricitinib in patients with Rheumatoid Arthritis
* A randomized, double-blind, parallel group, multicenter study to demonstrate similar efficacy and to compare safety and immunogenicity of GP2017 and Humaira® in patients with moderate to severe active rheumatoid arthritis, 2016
* A phase 3, multicenter, long-term observational study of subjects from Tanezumab studies who undergo total knee, hip or shoulder replacement, 2016
* A phase 3, randomized, double blind, active-controlled, multicenter study of the long-term safety and efficacy of subcutaneous administration of Tanezumab in subjects with osteoarthritis of the hip or knee, 2016

**Sub- Investigator**

* A randomized, double-blind, active control, multicenter study to evaluate the efficacy at week 52 of subcutaneously administered secukinumab monotherapy compared with subcutaneously administered adalimumab monotherapy in patients with active psoriatic arthritis. 2018
* A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects with Active Psoriatic Arthritis including those Previously Treated with Biologic Anti-TNFα Agent(s) 2017
* A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects with Active Psoriatic Arthritis. 2017
* A phase 3, randomized, double blind, active-controlled, multicenter study of the long-term safety and efficacy of subcutaneous administration of Tanezumab in subjects with osteoarthritis of the hip or knee, 2015
* A multicenter, randomized, double-blind, study comparing the efficacy and safety of continuing versus withdrawing Adalimumab therapy in maintaining remission in subjects with non-radiographic axial spondyloarthritis, 2013
* A multi-center, randomized, double-blind, saline-controlled study of a single injection of Durolane versus a single injection of phosphate buffered saline (PBS) to treat pain associated with osteoarthritis of the knee, 2013
* A phase 3, multicenter study to evaluate the long term safety and efficacy of Baricitinib in patients with rheumatoid arthritis, 2013
* A randomized, double-blind, placebo-and active-controlled, phase 3 study to evaluating the efficacy and safety of Baricitinib in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to Methotrexate therapy, 2012
* A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of Baricitinib(LY3009104) in patients with inadequate response to conventional disease- modifying antirheumatic drugs with moderately to severely active rheumatoid arthritis, 2012
* A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol alone in Subjects with Gout who have had an Inadequate Hypouricemic Response to Standard of Care Allopurinol. 2012
* Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO). 2012
* A randomized, double-blind, placebo-controlled, phase 3 study evaluating the efficacy and safety of Baricitinib (LY3009104) in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors, 2012
* A phase IV, multicenter, randomized, 52-week study to evaluate the routine assessment of Patient Index Data (RAPID3) compared to the Clinical Disease Activity Index (CDAI) to prospectively predict treatment success at 52 weeks based on a treatment decision at week 12 in subjects with moderate to severe rheumatoid arthritis receiving Certolizumab Pegol (CZP), 2010
* A multicenter, randomized, active-control, phase 3B study to evaluate the cardiovascular safety of Febuxostat and Allopurinol in subjects with gout and cardiovascular comorbidities, 2010
* A multicenter, double-blind, randomized, parallel-arm study to determine the effect of methotrexate dose on clinical outcome and ultrasonographic signs in subjects with moderately to severely active rheumatoid arthritis treated with Adalimumab, 2010
* A phase III, multi-center, randomized, double-blind, placebo-controlled, parallel group study of two dosing regimens of Fostamatinib Disodium in rheumatoid arthritis patients with inadequate response to a TNF-alpha antagonist
* A phase IV, multicenter, randomized, 52-week study to evaluate the routine assessment of Patient Index Data (RAPID3) compared to the Clinical Disease Activity Index (CDAI) to prospectively predict treatment success at 52 weeks based on a treatment decision at week 12 in subjects with moderate to severe rheumatoid arthritis receiving Certolizumab Pegol (CZP), 2010
* A multicenter, randomized, active-control, phase 3B study to evaluate the cardiovascular safety of Febuxostat and Allopurinol in subjects with gout and cardiovascular comorbidities, 2010
* A randomized, controlled study of ACZ885 (canakinumab) on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or Colchicine are contraindicated, not tolerated or ineffective, 2009
* A multicenter, randomized, double-blind, placebo-controlled switch study to evaluate the safety, tolerability and efficacy of Milnacipran in patients with an inadequate response to Duloxetine for the treatment of fibromyalgia, Rollover, 2009
* A multicenter, randomized, double-blind, placebo-controlled switch study to evaluate the safety, tolerability and efficacy of Milnacipran in patients with an inadequate response to Duloxetine for the treatment of fibromyalgia, 2009
* An open-label, randomized study to evaluate the safety, tolerability and efficacy of tocilizumab(TCV) monotherapy or TCZ in combination with non-biologic disease modifying antirheumatic drugs(DMARDs) in patients with active rheumatoid arthritis who have an inadequate response to current non-biologic or biologic DMARDs, 2009
* Phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of 2 doses of CP-690,550 in patients with active rheumatoid arthritis on background DMARDs, 2009
* A multicenter, randomized, open-label, controlled study to evaluate the safety, tolerability and efficacy of Milnacipran when added to Pregabalin in the treatment of fibromyalgia, 2009
* A phase 3, multicenter, randomized, long term study of the safety of Tanezumab in patients with osteoarthritis of the knee or hip, 2009
* A phase 3 randomized, double-blind, placebo-controlled multicenter study of the analgesic efficacy and safety of Tanezumab in patients with osteoarthritis of the hip, 2009
* A Phase 3 randomized, double-blind, placebo-controlled multicenter study of the analgesic efficacy and safety of Tanezumab in patients with osteoarthritis of the knee, 2009
* A Phase IIIb, multicenter study with a 12-week double-blind, placebo-controlled, randomized period followed by an open-label, extension phase to evaluate the safety and efficacy of certolizumab pegol administered to patients with active rheumatoid arthritis, 2008
* Flexible dosed Duloxetine versus Placebo in the treatment of Fibromyalgia study, 2008
* The Efficacy and Safety of TDS-943 in the Treatment of Osteoarthritis of the Knee: Pivotal Study II, 2008
* A Phase IIIB, Multicenter, Randomized, Double-Blind, Double-Dummy Study to Evaluate the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects with Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate, 2008
* A Phase 3, Randomized, Multicenter, Double-Blind, Allopurinol-Controlled Study Assessing the Efficacy and Safety of Oral Febuxostat in Subjects with Gout, 2007
* A Long-Term Study Of The Safety Of Rituxan In Patients With Rheumatoid Arthritis After An Inadequate Response To Previous Anti-TNF Therapy, 2007
* A Multi-Center, Randomized, Double-Blind, Controlled, Parallel-Group Study of a Single Intra-Articular Injection of Gel-200 with a Single Intra-Articular Injection of Phosphate Buffered Saline (PBS) in Osteoarthritis of the Knee, 2006
* A phase III Pivotal, Multi-center, Double-blind, Randomized, Placebo-Controlled, Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia, 2006